Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa

  • Guide, Shireen V. M.D.
  • Gonzalez, Mercedes E. M.D.
  • Bağcı, I. Sinem M.D.
  • Agostini, Brittani B.S.N.
  • Chen, Hubert M.D.
  • Feeney, Gloria B.S.
  • Steimer, Molly B.S.
  • Kapadia, Binoy B.S.
  • Sridhar, Kunju Ph.D.
  • Quesada Sanchez, Lori B.S.
  • Gonzalez, Franshesca B.S.
  • Van Ligten, Matthew B.S.
  • Parry, Trevor J. Ph.D.
  • Chitra, Surya Ph.D.
  • Kammerman, Lisa A. Ph.D.
  • Krishnan, Suma M.S.
  • Marinkovich, M. Peter M.D.

  • From the Mission Dermatology Center, Department of Dermatology, Children’s Hospital of Orange County, University of California Irvine, Rancho Santa Margarita (S.V.G., M.V.L.), the Department of Dermatology, Stanford University School of Medicine, Stanford (I.S.B., K.S., M.P.M.), and the Veterans Affairs Medical Center, Palo Alto (M.P.M.) — all in California; Pediatric Skin Research, Coral Gables, FL (M.E.G., L.Q.S., F.G.); Krystal Biotech, Pittsburgh (B.A., H.C., G.F., M.S., B.K., T.J.P., S.K.); Savio Group Analytics, Hockessin, DE (S.C.); and Kammerman Consulting, Chevy Chase, MD (L.A.K.).

Dr. Marinkovich can be contacted at [email protected] at the Department of Dermatology, Stanford University School of Medicine, 455 Broadway St., Redwood City, CA 94063.Drs. Guide, M. Gonzalez, and Bağcı contributed equally to this article.http://www.nejmgroup.org/legal/terms-of-use.htm

New England Journal of Medicine 387(24):p 2211-2219, December 15, 2022. | DOI: 10.1056/NEJMoa2206663

Corresponding Article

The Coming of Age of Topical Gene Therapy for Dystrophic Epidermolysis Bullosa

  • Schaffer, David V. Ph.D.
New England Journal of Medicine 387(24):p 2279-2280, December 15, 2022. | DOI: 10.1056/NEJMe2212899
Copyright © 2022 Massachusetts Medical Society. All rights reserved.
View full text|Download PDF